Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-29T17:38:23.587Z Has data issue: false hasContentIssue false

21 - Polycystic ovary syndrome ovulation induction

from Section 4 - The tool kit

Published online by Cambridge University Press:  05 July 2015

By
Carolyn J. Alexander
Edited by
Leo Plouffe, Jr  and
Botros R. M. B. Rizk
Leo Plouffe, Jr
Affiliation:
Bayer Healthcare, Wayne, New Jersey
Botros R. M. B. Rizk
Affiliation:
University of South Alabama
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Androgens in Gynecological Practice , pp. 216 - 225
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bates, GW, Propst, AM. Polycystic ovarian syndrome management options. Obstet Gynecol Clin North Am 2012 ; 39(4):495–506. Use of clomiphene citrate in women. Fertil Steril 2006;86(5):187–93.CrossRefGoogle ScholarPubMed
2.Dovey, S, Sneeringer, R, Penzias, A. Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. Fertil Steril 2008;90(6):2281–6.CrossRefGoogle ScholarPubMed
3.Imani, B. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002;71(1):91–7.Google Scholar
4.Kafy, S, Tulandi, T. New advances in ovulation induction. Curr Opin Obstet Gynecol 2007;19(3):248–52.Google Scholar
5.Brown, J, Farquhar, C, Beck, J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;4(4). Art. No.: CD002249.Google Scholar
6.Costello, MF, Misso, ML, Wong, J, et al. The treatment of infertility in PCOS: a brief update. Aust N Z J Obstet Gynaecol 2012;52(4):400–3.Google Scholar
7.Forman, R, Gill, S, Moretti, M, et al. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can 2007;29(8):668–71.Google Scholar
8.Tulandi, T, Martin, J, Al-Fadhli, R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006;85(6):1761–5.CrossRefGoogle ScholarPubMed
9.Brown, MM, Hemmings, R, Brassard, N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 2005;84 (Suppl 1); O–231, Abstract 1033.Google Scholar
10.Mitwally, MF, Casper, RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75(2):305–9.CrossRefGoogle ScholarPubMed
11.Pritts, EA, Yuen, AK, Sharma, S, et al. The use of high dose letrozole in ovulation induction and controlled ovarian hyperstimulation. ISRN Obstet Gynecol 2011;2011:242864.CrossRefGoogle ScholarPubMed
12.Kamath, MS, Aleyamma, TK, Chandy, A, George, K. Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2010;94(7):2857–9.CrossRefGoogle ScholarPubMed
13.Misso, ML, Wong, J, Teede, HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update 2012;18(3):301–12.Google Scholar
14.Nahid, L, Sirous, K. Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. Minerva Ginecol 2012; 64(3):253–8.Google Scholar
15.Kar, S. Current evidence supporting “letrozole” for ovulation induction. J Hum Reprod Sci. 2013;6(2):93–8.CrossRefGoogle ScholarPubMed
16.Kamat, A, Hinshelwood, MM, Murry, BA, Mendelson, CR. Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab 2002;13(3):122–8.Google Scholar
17.Mason, AJ, Berkemeier, LM, Schmelzer, CH, Schwall, RH. Activin B: precursor sequences, genomic structure and in vitro activities. Mol Endocrinol 1989;3(9):1352–8.Google Scholar
18.Naftolin, F, MacLusky, NJ. Aromatization hypothesis revisisted. In: Serio, M (Ed.). Differentiation Basic and Clinical Aspects. New York: Raven Press; 1984. pp. 79–91.Google Scholar
19.Naftolin, F, MacLusky, NJ, Leranth, CZ, et al. The cellular effects of estrogens on neuroendocrine tissue. J Steroid Biochem 1988;30(1–6):195–207.CrossRefGoogle Scholar
20.Naftolin, F. Brain aromatization of androgens. J Reprod Med 1994;39(4):257–61.Google ScholarPubMed
21.Roberts, V, Meunier, H, Vaughan, J, et al. Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology 1989;124(1):552–4.Google Scholar
22.Vendola, KA, Zhou, J, Adesanya, OO, Weil, SJ, Bondy, CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101(12):2622–9.CrossRefGoogle ScholarPubMed
23.Weil, SJ, Vendola, K, Zhou, J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998;83(7):2479–85.Google Scholar
24.Weil, S, Vendola, K, Zhou, J, Bondy, CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999;84(8):2951–6.CrossRefGoogle ScholarPubMed
25.Nestler, JE, Jakubowicz, DJ, Reamer, P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340(17):1314–20.Google Scholar
26.Azziz, R, Ehrmann, D, Legro, RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86(4):1626–32.Google ScholarPubMed
27.Creanga, AA, Bradley, HM, McCormick, C, Witkop, CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008;111(4):959–68.Google Scholar
28.Ghazeeri, G, Kutteh, WH, Bryer-Ash, M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79(3):562–6.Google Scholar
29.Baillargeon, JP, Jakubowicz, DJ, Iuorno, MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82(4):893–902.Google Scholar
30.Carmina, E, Lobo, RA. Does metformin induce ovulation in normoandrogenic anovulatory women? Am J Obstet Gynecol 2004;191(5):1580–4.Google Scholar
31.Nestler, JE, Jakubowicz, DJ, Evans, WS, Pasquali, R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338(26):1876–80.Google Scholar
32.Perales-Puchalt, A, Legro, RS. Ovulation induction in women with polycystic ovary syndrome. Steroids 2003;78(8): 767–72.Google Scholar
33.Barbieri, RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol 2003;101(4):785–93.Google Scholar
34.Haas, DA, Carr, BR, Attia, GR. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003;79(3):469–81.CrossRefGoogle ScholarPubMed
35.Maciel, GA, Soares Junior, JM, Alves da Motta, EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81(2):355–60.Google Scholar
36.Nestler, JE, Jakubowicz, DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335(9):617–23.Google Scholar
37.Niskanen, L, Uusitupa, M, Sarlund, H, et al. The effects of weight loss on insulin sensitivity, skeletal muscle composition and capillary density in obese nondiabetic subjects. Int J Obes Relat Metab Disord 1996;20(2):154–60.Google Scholar
38.Pasquali, R, Antenucci, D, Casimirri, F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68(1):173–9.Google Scholar
39.Bates, GW, Whitworth, NS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 1982;38(4):406–9.CrossRefGoogle ScholarPubMed
40.Guzick, DS, Wing, R, Smith, D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;61(4):598–604.Google Scholar
41.Barbieri, R, Ehrmann, D, Snyder, P, et al. Metformin for treatment of the polycystic ovary syndrome. www-uptodate-com.libproxy.usc.edu/contents/metformin-for-treatment-of-the-polycystic-ovarysyndrome?detectedLanguage=en&source=search_result&search=metformin+pcos&selectedTitle=1~150&provider=noProvider#H12.Google Scholar
42.Blonde, L, Dailey, GE, Jabbour, SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20(4): 565–72.Google Scholar
43.Ikeda, T, Iwata, K, Murakami, H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol 20001;59(7):887–90.Google Scholar
44.DeFronzo, RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131(4):281–303.Google Scholar
45.Lord, JM, Flight, IH, Norman, RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;(3):CD003053.Google Scholar
46.Cosma, M, Swiglo, BA, Flynn, DN, et al. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008;93(4):1135–42.Google Scholar
47.Martin, KA, Chang, RJ, Ehrmann, DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical practice guideline. J Clin Endocrinol Metab 2008;93(4):1105–20.CrossRefGoogle ScholarPubMed
48.Lord, JM, Flight, IH, Norman, RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951–3.CrossRefGoogle ScholarPubMed
49.Moll, E, Bossuyt, PM, Korevaar, JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332(7556):1485.Google Scholar
50.Legro, RS, Barnhart, HX, Schlaff, WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356(6):551–66.Google Scholar
51.Zain, MM, Jamaluddin, R, Ibrahim, A, Norman, RJ. Comparison of clomiphene citrate, metformin, or the combination of both for firstline ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial, Fertil Steril 2009;91(2):514–21.CrossRefGoogle ScholarPubMed
52.Vandermolen, DT, Ratts, VS, Evans, WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75(2):310–15.Google Scholar
53.Kocak, M, Caliskan, E, Simsir, C, Haberal, A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome, Fertil Steril 2002;77(1):101–6.CrossRefGoogle ScholarPubMed
54.Malkawi, HY, Qublan, HS. The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome, Saudi Med J 2002;23(6):663–6.Google ScholarPubMed
55.Hwu, YM, Lin, SY, Huang, WY, Lin, MH, Lee, RK. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome, Int J Gynaecol Obstet 2005;90(1):39–43.Google Scholar
56.Fritz, MA., Speroff, L. Induction of ovulation. In: Clinical Gynecologic Endocrinology and Infertility, 8th edn. Baltimore, MD: Lippincott Williams & Wilkins, 2011.Google Scholar
57.Tang, T, Lord, JM, Norman, RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;5:CD003053.Google Scholar
58.Rouzi, AA, Ardawi, MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2006;85(2):428–35.Google Scholar
59.Kaul, S, Bolger, AF, Herrington, D, Giugliano, RP, Eckel, RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation, J Am Coll Cardiol 2010;55(17):1885–94.Google Scholar
60.Misso, ML, Teede, HJ, Hart, R, et al. Status of clomiphene citrate and metformin for infertility in PCOS. Trends Endocrinol Metab 2012;23(10):533–43.Google Scholar
61.Wide, L, Naessen, T, Sundstrom-Poromaa, I, Eriksson, K. Sulfonation and sialylation of gonadotropins in women during the menstrual cycle, after menopause, and with polycystic ovarian syndrome and in men. J Clin Endocrinol Metab 2007;92(11):4410–17.CrossRefGoogle ScholarPubMed
62.Barrios-De-Tomasi, J, Timossi, C, Merchant, H, et al. Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones. Mol Cell Endocrinol 2002;186(2):189–98.Google Scholar
63.Andersen, CY, Leonardsen, L, Ulloa-Aguirre, A, et al. Effect of different FSH isoforms on cyclic-AMP production by mouse cumulus-oocyte-complexes: a time course study. Mol Hum Reprod 2001;7(2):129–35.Google Scholar
64.Lunenfeld, B. Historical perspectives in gonadotropin therapy. Hum Reprod Update 2004;10(6):453–67.Google Scholar
65.Casper, RF. Are recombinant gonadotrophins safer, purer and more effective than urinary gonadotrophins?, Reprod Biomed Online 2005;11(5):539–40.CrossRefGoogle ScholarPubMed
66.Filicori, M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril 1999;71(3):405–14.Google Scholar
67.Whelan, JG, 3rd, Vlahos, NF. The ovarian hyperstimulation syndrome, Fertil Steril 2000;73(5):883–96.Google Scholar
68.Schmidt, GE, Kim, MH, Mansour, R, et al. The effects of enclomiphene and zuclomiphene citrates on mouse embryos fertilized in vitro and in vivo, Am J Obstet Gynecol 1986;154(4):727–36.Google Scholar
69.Nugent, D, Vandekerckhove, P, Hughes, E, et al. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000;(4):CD000410.Google Scholar
70.Bayram, N, van Wely, M, van Der Veen, F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome, Cochrane Database Syst Rev 2001;(2):CD002121.Google ScholarPubMed
71.Van Wely, M, Bayram, N, van der Veen, F. Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 2003;18(6):1143–9.CrossRefGoogle ScholarPubMed
72.Van Der Meer, M, Hompes, PG, De Boer, JA, et al. Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83(2):423–6.Google ScholarPubMed
73.Shoham, Z, Patel, A, Jacobs, HS. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 1991;55(6):1051–6.Google Scholar
74.Hamilton-Fairley, D, Kiddy, D, Watson, H, et al. Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 1991;6(8):1095–9.Google Scholar
75.Grigoriou, O, Antoniou, G, Antonaki, V, et al. Low-dose follicle-stimulating hormone treatment for polycystic ovarian disease. Int J Gynaecol Obstet 1996;52(1):55–9.Google Scholar
76.Ergur, AR, Yergok, YZ, Ertekin, A, et al. Clomiphene citrate-resistant polycystic ovary syndrome. Preventing multifollicular development. J Reprod Med 1998;43(3):185–90.Google ScholarPubMed
77.Homburg, R, Levy, T, Ben-Rafael, Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995; 63(4):729–33.Google Scholar
78.White, DM, Polson, DW, Kiddy, D. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81(11):3821–4.Google Scholar
79.Kamrava, MM, Seibel, MM, Berger, MJ, et al. Reversal of persistent anovulation in polycystic ovarian disease by administration of chronic low-dose follicle-stimulating hormone. Fertil Steril 1982;37(4):520–3.Google Scholar
80.Polson, DW, Mason, HD, Saldahna, MB, Franks, S. Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1987;26(2):205–12.CrossRefGoogle ScholarPubMed
81.Messinis, IE, Milingos, SD. Current and future status of ovulation induction in polycystic ovary syndrome. Hum Reprod Update 1997;3(3):235–53.Google Scholar
82.Homburg, R, Howles, CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 1999;5(5):493–9.Google Scholar
83.Macklon, NS, Fauser, BC. The step-down protocol. In Tarlatzis, B (Ed.) Ovulation Induction. Paris, Elsevier, pp. 108–18.Google Scholar
84.Elchalal, U, Schenker, JG. The pathophysiology of ovarian hyperstimulation syndrome–views and ideas. Hum Reprod 1997;12(6):1129–37.Google Scholar
85.Kaiser, UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003;349(8):729–32.Google Scholar
86.Lee, TH, Liu, CH, Huang, CC, et al. Serum anti-mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008;23(1):160–7.Google Scholar
87.Esinler, I, Bayar, U, Bozdag, G, Yarali, H. Outcome of intracytoplasmic sperm injection in patients with polycystic ovary syndrome or isolated polycystic ovaries. Fertil Steril 2005;84(4):932–7.Google Scholar
88.North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75(1):38–45.Google Scholar
89.Rabinovici, J, Kushnir, O, Shalev, J, et al. Rescue of menotrophin cycles prone to develop ovarian hyperstimulation. Br J Obstet Gynaecol 1987;94(11):1098–102.CrossRefGoogle ScholarPubMed
90.Wada, I, Matson, PL, Troup, SA, et al. Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. Hum Reprod 1992;7(7):962–6.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×